Candidate Compound
Yuhan Corporation announced on May 30 that it has signed a technology licensing agreement with J INTS BIO for the tyrosine kinase inhibitor (TKI) “JIN-A04” targeting HER2.
The total contract size amounts to 429.8 billion won (US$325.8 million), inclusive of an upfront payment of 25 billion won (US$19 million) and step-by-step milestones contingent on future development, authorization, and sales.
JIN-A04 is an oral TKI candidate substance targeting the HER2 gene of non-small cell lung cancer. So far, there are no approved oral drugs targeting this gene.
At the American Association for Cancer Research (AACR) Annual Meeting 2023, J INTS BIO revealed preclinical results of JIN-A04 in a poster presentation, highlighting its strong efficacy in both in vitro and in vivo studies.
President Cho Wook-je of Yuhan Corporation said, "We believe the signing of this contract is a significant step towards developing our second and third line of oncology therapeutics," and added, "We will focus all our capabilities to swiftly proceed to clinical trials and continue to strengthen our oncology pipeline."